

# Fabrice Carrat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6545654/publications.pdf>

Version: 2024-02-01

320  
papers

19,240  
citations

13865

67  
h-index

15266

126  
g-index

344  
all docs

344  
docs citations

344  
times ranked

20051  
citing authors

#	ARTICLE	IF	CITATIONS
1	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 38-49.	3.9	5
2	Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort). Cannabis and Cannabinoid Research, 2022, 7, 677-689.	2.9	6
3	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Reports, 2022, 4, 100390.	4.9	15
4	Association of Self-reported COVID-19 Infection and SARS-CoV-2 Serology Test Results With Persistent Physical Symptoms Among French Adults During the COVID-19 Pandemic. JAMA Internal Medicine, 2022, 182, 19.	5.1	183
5	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). Liver International, 2022, 42, 249-252.	3.9	3
6	Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France. Infection, 2022, 50, 257-262.	4.7	10
7	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. Lancet Regional Health - Europe, The, 2022, 13, 100278.	5.6	109
8	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
9	Estimating the burden of influenza-related and associated hospitalizations and deaths in France: An eight-season data study, 2010-2018. Influenza and Other Respiratory Viruses, 2022, 16, 717-725.	3.4	9
10	HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. Hepatology, 2022, 76, 139-154.	7.3	42
11	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619.	5.0	8
12	Metabolic Disorders in Patients with Chronic Hepatitis B Virus Infection: Coffee as a Panacea? (ANRS Tj ETQq0 0 0 rgBT /Overlock 10 Tf 55)	5.1	3
13	Comparing SF-36 Scores Collected Through Web-Based Questionnaire Self-completions and Telephone Interviews: An Ancillary Study of the SENTIPAT Multicenter Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e29009.	4.3	8
14	Emotional and attention-deficit/hyperactivity disorder symptoms of preterm vs. full-term children during COVID-19 pandemic restrictions. Pediatric Research, 2022, 92, 1749-1756.	2.3	6
15	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	4.9	3
16	Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of Infection, 2022, 84, e101-e104.	3.3	15
17	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	4.9	10
18	Persistent symptoms after the first wave of COVID-19 in relation to SARS-CoV-2 serology and experience of acute symptoms: A nested survey in a population-based cohort. Lancet Regional Health - Europe, The, 2022, 17, 100363.	5.6	12

#	ARTICLE	IF	CITATIONS
19	Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France. <i>Viruses</i> , 2022, 14, 957.	3.3	5
20	Multilabel classification of medical concepts for patient clinical profile identification. <i>Artificial Intelligence in Medicine</i> , 2022, 128, 102311.	6.5	10
21	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617.		2
22	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. <i>Scientific Reports</i> , 2022, 12, .	3.3	8
23	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1545-1553.	3.7	33
24	Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort. <i>Journal of Cannabis Research</i> , 2022, 4, .	3.2	1
25	Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. <i>Journal of Infection</i> , 2022, 85, e104-e108.	3.3	29
26	Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101459.	1.5	4
27	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. <i>Journal of Hepatology</i> , 2021, 74, 37-47.	3.7	21
28	Effectiveness of direct acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. <i>Liver International</i> , 2021, 41, 2328-2340.	3.9	3
29	Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. <i>BMC Infectious Diseases</i> , 2021, 21, 169.	2.9	33
30	Evidence of early circulation of SARS-CoV-2 in France: findings from the population-based "CONSTANCES" cohort. <i>European Journal of Epidemiology</i> , 2021, 36, 219-222.	5.7	54
31	When lockdown policies amplify social inequalities in COVID-19 infections: evidence from a cross-sectional population-based survey in France. <i>BMC Public Health</i> , 2021, 21, 705.	2.9	44
32	Liver fibrosis and all-cause mortality in chronic HCV-infected diabetic patients: A paradoxical association? (ANRS CO22 HEPATHER). <i>Liver International</i> , 2021, 41, 1694-1698.	3.9	0
33	Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population. <i>Infectious Diseases Now</i> , 2021, 51, 380-382.	1.6	28
34	Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study. <i>Lancet Public Health</i> , The, 2021, 6, e408-e415.	10.0	54
35	Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. <i>International Journal of Epidemiology</i> , 2021, 50, 1458-1472.	1.9	75
36	Nationwide Seroprevalence of SARS-CoV-2 IgG Antibodies among Four Groups of Primary Health-Care Workers and Their Household Contacts 6 Months after the Initiation of the COVID-19 Vaccination Campaign in France: SeroPRIM Study Protocol. <i>Pathogens</i> , 2021, 10, 911.	2.8	6

#	ARTICLE	IF	CITATIONS
37	Seasonal burden of severe influenza virus infection in the critically ill patients, using the Assistance Publique-Hôpitaux de Paris clinical data warehouse: a pilot study. <i>Annals of Intensive Care</i> , 2021, 11, 117.	4.6	3
38	Association Between FIASMAs and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: An Observational Multicenter Study. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1498-1511.	4.7	59
39	Body weight, body composition and the risk of SARS-CoV-2 infection in a large population-based sample. <i>Journal of Internal Medicine</i> , 2021, 290, 1268-1271.	6.0	1
40	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298.	4.9	6
41	Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study. <i>Lancet Regional Health - Europe</i> , The, 2021, 7, 100148.	5.6	57
42	Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. <i>HIV Medicine</i> , 2021, 22, 924-935.	2.2	2
43	Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 565-571.	3.7	53
44	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101713.	1.5	10
45	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. <i>Journal of Clinical Virology</i> , 2021, 144, 104987.	3.1	2
46	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100171.	5.6	70
47	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1138-1146.	3.7	37
48	Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1050-1050.	3.7	1
49	Nutritional risk factors for SARS-CoV-2 infection: a prospective study within the NutriNet-Santé cohort. <i>BMC Medicine</i> , 2021, 19, 290.	5.5	26
50	Children's mental and behavioral health, schooling, and socioeconomic characteristics during school closure in France due to COVID-19: the SAPRIS project. <i>Scientific Reports</i> , 2021, 11, 22373.	3.3	15
51	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir—new clues from Europe. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 659-659.	3.7	0
52	Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. <i>Gut</i> , 2020, 69, 852-858.	12.1	46
53	Comparing interferon-free with interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox. <i>Journal of Viral Hepatitis</i> , 2020, 27, 329-332.	2.0	1
54	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020, 19, 102446.	5.8	13

#	ARTICLE	IF	CITATIONS
55	Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 879-884.	3.4	21
56	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C infected patients (ANRS Tj ETQq0 0.0 rgBT / Overlock 10	2.0	13
57	Predictive models for hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis C and sustained virological response (SVR) achieved with direct acting anti-viral (DAA) included in the ANRS CO22 hepather cohort. <i>Journal of Hepatology</i> , 2020, 73, S106.	3.7	2
58	Cost-effectiveness of scaling-up treatment with nucleoside analogue (NA) for chronic HBV infection: Towards a simplification of recommendations? (ANRS study). <i>Journal of Hepatology</i> , 2020, 73, S797-S798.	3.7	2
59	Sofosbuvir+Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. <i>Journal of Viral Hepatitis</i> , 2020, 27, 964-973.	2.0	5
60	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	3.7	52
61	Non-influenza respiratory viruses in adult patients admitted with influenza-like illness: a 3-year prospective multicenter study. <i>Infection</i> , 2020, 48, 489-495.	4.7	23
62	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	3.7	47
63	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	3.9	66
64	Biased and unbiased estimation of the average length of stay in intensive care units in the Covid-19 pandemic. <i>Annals of Intensive Care</i> , 2020, 10, 135.	4.6	25
65	Acute and Chronic Sarcoid Arthropathies: Characteristics and Treatments From a Retrospective Nationwide French Study. <i>Frontiers in Medicine</i> , 2020, 7, 565420.	2.6	5
66	The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1489-1492.	2.0	13
67	Genetic diversity of genotype 6 HCV infections in France: Epidemiology and consequences for treatment strategy. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1276-1283.	2.0	1
68	SAT-490-No impact of direct-acting antivirals on recurrent hepatocellular carcinoma tumour growth in the ANRS CO22 Hepather Cohort. <i>Journal of Hepatology</i> , 2019, 70, e849-e850.	3.7	0
69	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules – A response. <i>Journal of Hepatology</i> , 2019, 71, 446.	3.7	2
70	GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts. <i>Journal of Hepatology</i> , 2019, 70, e2-e3.	3.7	11
71	Direct-acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic?. <i>Liver International</i> , 2019, 39, 446-447.	3.9	0
72	Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 300.	2.9	5

#	ARTICLE	IF	CITATIONS
73	Ischemic stroke in giant-cell arteritis: French retrospective study. <i>Journal of Autoimmunity</i> , 2019, 99, 48-51.	6.5	38
74	Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. <i>Lancet, The</i> , 2019, 393, 1453-1464.	13.7	449
75	Inflammatory disorders associated with trisomy 8â€“myelodysplastic syndromes: French retrospective caseâ€“control study. <i>European Journal of Haematology</i> , 2019, 102, 63-69.	2.2	20
76	Gastrointestinal Behcetâ€™s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1782-1788.	1.3	22
77	Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study. <i>Joint Bone Spine</i> , 2019, 86, 523-524.	1.6	0
78	Letter: more studies are needed to elucidate the impact of <scp>HBV</scp>/<scp>HCV</scp> coinfection on cirrhosis and its consequencesâ€“Authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 543-544.	3.7	0
79	Phenotypes and survival in Erdheimâ€“Chester disease: Results from a 165â€“patient cohort. <i>American Journal of Hematology</i> , 2018, 93, E114-E117.	4.1	94
80	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohnâ€™s Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 892-899.e2.	4.4	80
81	Increased risk of acute arterial events in young patients and severely active IBD: a nationwide French cohort study. <i>Gut</i> , 2018, 67, 1261-1268.	12.1	104
82	Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?. <i>Clinical Infectious Diseases</i> , 2018, 66, 317-318.	5.8	4
83	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1399-1405.	1.3	21
84	Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 337-346.e10.	1.3	411
85	Signal detection on a patient cohort: A disproportionality analysis of the ANRS CO22 HEPATHER cohort to identify associations between direct acting antivirals and adverse events in patients with hepatitis C virus chronic infection. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 797-805.	1.9	3
86	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 177-188.	8.1	79
87	Coronary heart disease is associated with a worse clinical outcome of hand osteoarthritis: a cross-sectional and longitudinal study. <i>RMD Open</i> , 2017, 3, e000344.	3.8	24
88	Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 730-734.	5.8	63
89	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , 2017, 10, 605-614.	2.7	4
90	Immunity against influenza A(H1N1) infections is determined by age at the time of initial strain circulation. <i>Epidemiology and Infection</i> , 2017, 145, 141-147.	2.1	3

#	ARTICLE	IF	CITATIONS
91	Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 261-276.	2.1	12
92	Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France. <i>Clinical Microbiology and Infection</i> , 2017, 23, 253-259.	6.0	60
93	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 533-541.	3.7	35
94	The negative impact of <scp>HBV</scp>/<scp>HCV</scp> coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1054-1060.	3.7	66
95	Effect of resistance-associated substitutions on retreatment of direct acting antiviral-exposed patients in the real-world setting (ANRS CO22 HEPATHER). <i>Journal of Hepatology</i> , 2017, 66, S84.	3.7	3
96	Immune activation, smoking, and vaccine response. <i>Aids</i> , 2017, 31, 171-173.	2.2	12
97	Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1679.	7.4	424
98	Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. <i>Autoimmunity Reviews</i> , 2017, 16, 903-910.	5.8	32
99	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). <i>Blood</i> , 2017, 130, 1377-1380.	1.4	146
100	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 152-163.	7.3	93
101	Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients. <i>Journal of Hepatology</i> , 2017, 66, 39-47.	3.7	100
102	Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. <i>PLoS ONE</i> , 2017, 12, e0163586.	2.5	49
103	Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. <i>BMC Medical Research Methodology</i> , 2017, 17, 160.	3.1	9
104	Comparing Inpatient Satisfaction Collected via a Web-Based Questionnaire Self-Completion and Through a Telephone Interview: An Ancillary Study of the SENTIPAT Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2017, 19, e293.	4.3	8
105	Testing for hepatitis B virus alone does not increase vaccine coverage in non-immunized persons. <i>World Journal of Gastroenterology</i> , 2017, 23, 7037-7046.	3.3	6
106	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. <i>PLoS ONE</i> , 2016, 11, e0157191.	2.5	19
107	Applications of Extreme Value Theory in Public Health. <i>PLoS ONE</i> , 2016, 11, e0159312.	2.5	40
108	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 252-261.	3.7	111



#	ARTICLE	IF	CITATIONS
109	A systematic review on the effect of the organisation of hospital discharge on patient health outcomes. <i>BMJ Open</i> , 2016, 6, e012287.	1.9	17
110	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	1.4	149
111	Heterogeneous shedding of influenza by human subjects and its implications for epidemiology and control. <i>Scientific Reports</i> , 2016, 6, 38749.	3.3	16
112	Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1. <i>JAMA Internal Medicine</i> , 2016, 176, 603.	5.1	31
113	Factors associated with poor outcomes among adults hospitalized for influenza in France: A three-year prospective multicenter study. <i>Journal of Clinical Virology</i> , 2016, 79, 68-73.	3.1	65
114	Reply to "A strong message is needed to address the issue of HCC recurrence after DAA therapy". <i>Journal of Hepatology</i> , 2016, 65, 1269-1270.	3.7	6
115	Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus coinfected patients. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1017-1026.	2.0	10
116	Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic?. <i>Pediatric Nephrology</i> , 2016, 31, 2299-2308.	1.7	29
117	Effectiveness of hepatitis B rapid tests toward linkage-to-care: results of a randomized, multicenter study. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 633-639.	1.6	9
118	Vaccination Against Hepatitis B Virus (HBV) in HIV-1 Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study. <i>Journal of Infectious Diseases</i> , 2016, 213, 1735-1742.	4.0	27
119	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1213-1224.	6.1	44
120	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , 2016, 11, e0156384.	2.5	19
121	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. <i>PLoS ONE</i> , 2016, 11, e0168640.	2.5	8
122	Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy. <i>Liver International</i> , 2015, 35, 1833-1844.	3.9	5
123	Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study. <i>Vaccine</i> , 2015, 33, 7015-7021.	3.8	3
124	Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study. <i>Liver International</i> , 2015, 35, 1950-1958.	3.9	16
125	IFI35, mir-99a and HCV Genotype to Predict Sustained Virological Response to Pegylated-Interferon Plus Ribavirin in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0121395.	2.5	8
126	Evaluation of Four Commercial Multiplex Molecular Tests for the Diagnosis of Acute Respiratory Infections. <i>PLoS ONE</i> , 2015, 10, e0130378.	2.5	58



#	ARTICLE	IF	CITATIONS
127	Simultaneous Human Immunodeficiency Virus-Hepatitis B-Hepatitis C Point-of-Care Tests Improve Outcomes in Linkage-to-Care: Results of a Randomized Control Trial in Persons Without Healthcare Coverage. Open Forum Infectious Diseases, 2015, 2, ofv162.	0.9	61
128	Towards an HBV cure: state-of-the-art and unresolved questionsâ€”report of the ANRS workshop on HBV cure. Gut, 2015, 64, 1314-1326.	12.1	234
129	Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimenâ€”The ANRS CO20-CUPIC study. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 443-450.	1.5	5
130	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and Bâ€œcell nonâ€œHodgkin lymphomas, ANRS HCâ€œ13 lymphoâ€œC study. American Journal of Hematology, 2015, 90, 197-203.	4.1	84
131	Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1283-1291.	9.1	45
132	Causal analysis of H1N1pdm09 influenza infection risk in a household cohort. Journal of Epidemiology and Community Health, 2015, 69, 272-277.	3.7	11
133	An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards. Journal of Hepatology, 2015, 62, 807-815.	3.7	54
134	Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study. Journal of Crohn's and Colitis, 2015, 9, 1096-1107.	1.3	43
135	Risk factors of pandemic influenza A / H 1 N 1 in a prospective household cohort in the general population: results from the C o P an F luâ€œF rance cohort. Influenza and Other Respiratory Viruses, 2015, 9, 43-50.	3.4	13
136	Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1135-7.	2.3	3
137	Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with <sc>HCV</sc>â€œgenotype 4 in <sc>E</sc>gypt. Journal of Viral Hepatitis, 2015, 22, 245-253.	2.0	35
138	Auto-Immune Origin of B Cells from HCV-Associated Lymphoma. Blood, 2015, 126, 1464-1464.	1.4	2
139	Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study. PLoS ONE, 2015, 10, e0145105.	2.5	4
140	Comparing Patientsâ€™ Opinions on the Hospital Discharge Process Collected With a Self-Reported Questionnaire Completed Via the Internet or Through a Telephone Survey: An Ancillary Study of the SENTIPAT Randomized Controlled Trial. Journal of Medical Internet Research, 2015, 17, e158.	4.3	8
141	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World Journal of Gastroenterology, 2015, 21, 5647.	3.3	13
142	Multiplex PCR performed of bronchoalveolar lavage fluid increases pathogen identification rate in critically ill patients with pneumonia: a pilot study. Annals of Intensive Care, 2014, 4, 35.	4.6	32
143	A Sero-epidemiological Study of Arboviral Fevers in Djibouti, Horn of Africa. PLoS Neglected Tropical Diseases, 2014, 8, e3299.	3.0	54
144	Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study. PLoS Computational Biology, 2014, 10, e1003568.	3.2	60

#	ARTICLE	IF	CITATIONS
145	Radiologic course of primary sclerosing cholangitis: Assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. <i>Hepatology</i> , 2014, 59, 242-250.	7.3	102
146	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 712-720.	3.7	59
147	Clinical validation of IFN $\beta$ /IL-10 and IFN $\beta$ /IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 104-113.	3.3	17
148	Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1324-1329.	4.4	86
149	Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response. <i>Journal of Infection</i> , 2014, 68, 462-466.	3.3	1
150	Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis. <i>Gastroenterology</i> , 2014, 147, 132-142.e4.	1.3	232
151	Determinants of individuals' risks to 2009 pandemic influenza virus infection at household level amongst Djibouti city residents - A CoPanFlu cross-sectional study. <i>Virology Journal</i> , 2014, 11, 13.	3.4	7
152	Statin and aspirin for prevention of hepatocellular carcinoma: What are the levels of evidence?. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 9-11.	1.5	20
153	Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: Results from the French nationwide CryoVas survey. <i>Autoimmunity Reviews</i> , 2014, 13, 630-634.	5.8	23
154	Public Health and Economic Impact of Vaccinating Children with a Quadrivalent live Attenuated Influenza Vaccine in France Using a Dynamic Transmission Model. <i>Value in Health</i> , 2014, 17, A674.	0.3	2
155	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014, 63, 1416-1423.	12.1	122
156	Using Pharmacokinetic and Viral Kinetic Modeling To Estimate the Antiviral Effectiveness of Telaprevir, Boceprevir, and Pegylated Interferon during Triple Therapy in Treatment-Experienced Hepatitis C Virus-Infected Cirrhotic Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5332-5341.	3.2	8
157	Detection of independent associations in a large epidemiologic dataset: a comparison of random forests, boosted regression trees, conventional and penalized logistic regression for identifying independent factors associated with H1N1pdm influenza infections. <i>BMC Medical Research Methodology</i> . 2014, 14, 99.	3.1	34
158	Influenza C virus high seroprevalence rates observed in 3 different population groups. <i>Journal of Infection</i> , 2014, 69, 182-189.	3.3	27
159	Baseline Values and Changes in Liver Stiffness Measured by Transient Elastography Are Associated With Severity of Fibrosis and Outcomes of Patients With Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2014, 146, 970-979.e6.	1.3	232
160	Reply to: From the CUPIC study: Great times are not coming (?). <i>Journal of Hepatology</i> , 2014, 60, 235-236.	3.7	0
161	Reply to: "From the CUPIC study: Great times are not coming (?)" <i>Journal of Hepatology</i> , 2014, 60, 900-901.	3.7	0
162	Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIEG study. <i>Journal of Hepatology</i> , 2014, 61, 761-769.	3.7	14

#	ARTICLE	IF	CITATIONS
163	Characterization of pandemic influenza immune memory signature after vaccination or infection. <i>Journal of Clinical Investigation</i> , 2014, 124, 3129-3136.	8.2	26
164	Current State of and Needs for Hepatitis B Screening: Results of a Large Screening Study in a Low-Prevalent, Metropolitan Region. <i>PLoS ONE</i> , 2014, 9, e92266.	2.5	15
165	Representations of influenza and influenza-like illness in the community - a qualitative study. <i>BMC Family Practice</i> , 2013, 14, 15.	2.9	14
166	Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. <i>Hepatology International</i> , 2013, 7, 437-442.	4.2	3
167	Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) â€“ NCT01514890. <i>Journal of Hepatology</i> , 2013, 59, 434-441.	3.7	407
168	Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France. <i>Journal of Hepatology</i> , 2013, 58, 473-478.	3.7	58
169	Complications and factors associated with severity of influenza in hospitalized children and adults during the pandemic wave of A(H1N1)pdm2009 infectionsâ€™The Fluco French cohort. <i>Journal of Clinical Virology</i> , 2013, 58, 114-119.	3.1	6
170	The influenza A (H1N1) pandemic in Reunion Island: knowledge, perceived risk and precautionary behaviour. <i>BMC Infectious Diseases</i> , 2013, 13, 34.	2.9	20
171	Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2013, 145, 166-175.e8.	1.3	311
172	Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008â€“2009 winter. <i>Clinical Microbiology and Infection</i> , 2013, 19, 196-203.	6.0	10
173	Longitudinal and Integrative Biomodeling of Effector and Memory Immune Compartments after Inactivated Influenza Vaccination. <i>Journal of Immunology</i> , 2013, 191, 623-631.	0.8	21
174	Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 374-380.	0.9	59
175	Field seasonal influenza vaccine effectiveness. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2453-2459.	3.3	9
176	Incidence, Presentation, and Prognosis of Small Bowel Adenocarcinoma in Patients with Small Bowel Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1.	1.9	53
177	Factors Associated with Post-Seasonal Serological Titer and Risk Factors for Infection with the Pandemic A/H1N1 Virus in the French General Population. <i>PLoS ONE</i> , 2013, 8, e60127.	2.5	21
178	2009 A(H1N1) Seroconversion Rates and Risk Factors among the General Population in Vientiane Capital, Laos. <i>PLoS ONE</i> , 2013, 8, e61909.	2.5	12
179	Trends in influenza vaccination behaviours â€“ results from the CoPanFlu cohort, France, 2006 to 2011. <i>Eurosurveillance</i> , 2013, 18, 20628.	7.0	25
180	Histological Characteristics Of Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. Results Of The French Lympho-C ANRS HC-13 Multicentric Study Of 133 Patients. <i>Blood</i> , 2013, 122, 3005-3005.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Risk of Melanoma in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Is Not Increased. <i>American Journal of Gastroenterology</i> , 2012, 107, 1443-1444.	0.4	31
182	Assessment and determinants of aesthetic discomfort in hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 45-49.	0.9	34
183	Effect of Oseltamivir, Zanamivir or Oseltamivir+ Zanamivir Combination Treatments on Transmission of Influenza in Households. <i>Antiviral Therapy</i> , 2012, 17, 1085-1090.	1.0	30
184	Long-term Outcomes of Pandemic 2009 Influenza A(H1N1)-Associated Severe ARDS. <i>Chest</i> , 2012, 142, 583-592.	0.8	199
185	Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. <i>Blood</i> , 2012, 119, 5996-6004.	1.4	175
186	A Short-Term, Multicomponent Infection Control Program in Nursing Homes: A Cluster Randomized Controlled Trial. <i>Journal of the American Medical Directors Association</i> , 2012, 13, 569.e9-569.e17.	2.5	23
187	Integrative study of pandemic A/H1N1 influenza infections: design and methods of the CoPanFlu-France cohort. <i>BMC Public Health</i> , 2012, 12, 417.	2.9	15
188	Simultaneous investigation of influenza and enteric viruses in the stools of adult patients consulting in general practice for acute diarrhea. <i>Virology Journal</i> , 2012, 9, 116.	3.4	24
189	Estimating influenza latency and infectious period durations using viral excretion data. <i>Epidemics</i> , 2012, 4, 132-138.	3.0	58
190	Intense Co-Circulation of Non-Influenza Respiratory Viruses during the First Wave of Pandemic Influenza pH1N1/2009: A Cohort Study in Reunion Island. <i>PLoS ONE</i> , 2012, 7, e44755.	2.5	34
191	Hepatitis E Virus Infection in Sheltered Homeless Persons, France. <i>Emerging Infectious Diseases</i> , 2012, 18, 1031-1032.	4.3	7
192	Broad respiratory virus detection in infants hospitalized for bronchiolitis by use of a multiplex RT-PCR DNA microarray system. <i>Journal of Medical Virology</i> , 2012, 84, 979-985.	5.0	64
193	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. <i>Hepatology</i> , 2012, 56, 198-208.	7.3	277
194	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2063-2071.	1.9	96
195	Severe transaminitis after interferon+ribavirin therapy in HIV/HCV+coinfectd patients: influence of a sustained HCV response. <i>Journal of Viral Hepatitis</i> , 2012, 19, 431-435.	2.0	4
196	Mortality Burden of the 2009 A/H1N1 Influenza Pandemic in France: Comparison to Seasonal Influenza and the A/H3N2 Pandemic. <i>PLoS ONE</i> , 2012, 7, e45051.	2.5	72
197	Contribution of Genome-Wide Association Studies to Scientific Research: A Bibliometric Survey of the Citation Impacts of GWAS and Candidate Gene Studies Published during the Same Period and in the Same Journals. <i>PLoS ONE</i> , 2012, 7, e51408.	2.5	16
198	Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. <i>Gut</i> , 2011, 60, 198-203.	12.1	160

#	ARTICLE	IF	CITATIONS
199	Integrating the applicability rate into the performance evaluation of noninvasive staging of liver fibrosis: A step towards a change from the "accuracy" to the "clinical" paradigm. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 691-692.	1.5	1
200	Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 1621-1628.e5.	1.3	431
201	Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. Journal of Hepatology, 2011, 55, 756-761.	3.7	89
202	Age distribution of cases and deaths during the 1889 influenza pandemic. Vaccine, 2011, 29, B6-B10.	3.8	15
203	Field Effectiveness of Pandemic and 2009-2010 Seasonal Vaccines against 2009-2010 A(H1N1) Influenza: Estimations from Surveillance Data in France. PLoS ONE, 2011, 6, e19621.	2.5	25
204	Low prevalence of colonoscopic surveillance of inflammatory bowel disease patients with longstanding extensive colitis: a clinical practice survey nested in the CESAME cohort. Alimentary Pharmacology and Therapeutics, 2011, 34, 188-195.	3.7	55
205	Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clinical Microbiology and Infection, 2011, 17, 732-737.	6.0	19
206	Impact of bucco-dental healthcare on the prevention of pneumonia in geriatrics: a cluster-randomised trial. Journal of Hospital Infection, 2011, 77, 78-80.	2.9	14
207	Guidelines for infection control in nursing homes: a Delphi consensus web-based survey. Journal of Hospital Infection, 2011, 79, 75-89.	2.9	21
208	Burden of infections among 44,869 elderly in nursing homes: a cross-sectional cluster nationwide survey. Journal of Hospital Infection, 2011, 79, 254-259.	2.9	36
209	Randomised active programs on healthcareworkers' flu vaccination in geriatric health care settings in France: The VESTA study. Journal of Nutrition, Health and Aging, 2011, 15, 126-132.	3.3	19
210	Nationwide surveillance of 18 respiratory viruses in patients with influenza-like illnesses: A pilot feasibility study in the French Sentinel Network. Journal of Medical Virology, 2011, 83, 1451-1457.	5.0	21
211	Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults With HIV-1. JAMA - Journal of the American Medical Association, 2011, 305, 1432.	7.4	157
212	Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis. New England Journal of Medicine, 2011, 365, 2067-2077.	27.0	683
213	Explaining rapid reinfections in multiple-wave influenza outbreaks: Tristan da Cunha 1971 epidemic as a case study. Proceedings of the Royal Society B: Biological Sciences, 2011, 278, 3635-3643.	2.6	43
214	Population Modeling of Influenza A/H1N1 Virus Kinetics and Symptom Dynamics. Journal of Virology, 2011, 85, 2764-2770.	3.4	90
215	Pandemic Influenza Due to pH1N1/2009 Virus: Estimation of Infection Burden in Reunion Island through a Prospective Serosurvey, Austral Winter 2009. PLoS ONE, 2011, 6, e25738.	2.5	22
216	Cost Effectiveness of Fibrosis Assessment Prior to Treatment for Chronic Hepatitis C Patients. PLoS ONE, 2011, 6, e26783.	2.5	41

#	ARTICLE	IF	CITATIONS
217	Risk perception and priority setting for intervention among hepatitis C virus and environmental risks: a cross-sectional survey in the Cairo community. BMC Public Health, 2010, 10, 773.	2.9	5
218	Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infectious Diseases, 2010, 10, 162.	2.9	97
219	Planning for the next influenza H1N1 season: a modelling study. BMC Infectious Diseases, 2010, 10, 301.	2.9	13
220	Surgical Mask to Prevent Influenza Transmission in Households: A Cluster Randomized Trial. PLoS ONE, 2010, 5, e13998.	2.5	84
221	Response to anti-HCV therapy in HIV/HCV-coinfected patients: does the lipid profile really have an effect?. Antiviral Therapy, 2010, 15, 797-800.	1.0	3
222	Transmissibility and geographic spread of the 1889 influenza pandemic. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8778-8781.	7.1	105
223	Comparison of Elastography, Serum Marker Scores, and Histology for the Assessment of Liver Fibrosis in Hepatitis B Virus (HBV)-Infected Patients in Burkina Faso. American Journal of Tropical Medicine and Hygiene, 2010, 82, 454-458.	1.4	66
224	WTWâ€”an algorithm for identifying “who transmits to whom” in outbreaks of interhuman transmitted infectious agents. Journal of the American Medical Informatics Association: JAMIA, 2010, 17, 348-353.	4.4	3
225	Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. Journal of Hepatology, 2010, 53, 238-244.	3.7	38
226	Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: The EPIB 2008 study. Journal of Hepatology, 2010, 53, 1006-1012.	3.7	46
227	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut, 2010, 59, 1363-1368.	12.1	155
228	Assessment of healthcare worker influenza vaccination program in French geriatric wards: a cluster-randomized controlled trial. Aging Clinical and Experimental Research, 2010, 22, 450-455.	2.9	13
229	Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality?. Therapeutics and Clinical Risk Management, 2009, 5, 491.	2.0	7
230	Diagnosis Scoring for Clinical Identification of Children With Heterozygous Familial Hypercholesterolemia. Journal of Pediatric Gastroenterology and Nutrition, 2009, 48, 456-463.	1.8	19
231	Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV/HCV co-infected patients. Alimentary Pharmacology and Therapeutics, 2009, 30, 61-70.	3.7	30
232	Mortality burden of the 1918-1919 influenza pandemic in Europe. Influenza and Other Respiratory Viruses, 2009, 3, 99-106.	3.4	113
233	Effect of Influenza Vaccination of Nursing Home Staff on Mortality of Residents: A Cluster-Randomized Trial. Journal of the American Geriatrics Society, 2009, 57, 1580-1586.	2.6	222
234	Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis. HIV Medicine, 2009, 10, 417-421.	2.2	5



#	ARTICLE	IF	CITATIONS
235	“If you have the flu symptoms, your asymptomatic spouse may better answer the willingness-to-pay question” Journal of Health Economics, 2009, 28, 873-884.	2.7	10
236	Liver biopsy: The best, not the gold standard. Journal of Hepatology, 2009, 50, 1-3.	3.7	289
237	Liver fibrosis: Screening is not staging. Journal of Hepatology, 2009, 50, 1268-1269.	3.7	4
238	281 Thiopurine Therapy Is Associated with a Three-Fold Decrease in the Incidence of Advanced Colorectal Neoplasia in IBD Patients with Longstanding Extensive Colitis: Results from the CESAME Cohort. Gastroenterology, 2009, 136, A-54.	1.3	16
239	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet, The, 2009, 374, 1617-1625.	13.7	996
240	Gamma Glutamyl Transferase Elevation in HIV/Hepatitis C Virus-Coinfected Patients During Interferon-Ribavirin Combination Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 429-430.	2.1	10
241	Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV“hepatitis C virus-coinfected patients: HOMAVIC-ANRS HC02 Study. Antiviral Therapy, 2009, 14, 839-845.	1.0	25
242	Targeted vs. systematic early antiviral treatment against A(H1N1)v influenza with neuraminidase inhibitors in patients with influenza-like symptoms: Clinical and economic impact. PLOS Currents, 2009, 1, RRN1121.	1.4	5
243	Effect of Antiviral Treatment on Serum Markers of Liver Fibrosis in HIV“Hepatitis C virus-Coinfected Patients: The Fibrovic 2 Study “ ANRS HC02. Antiviral Therapy, 2009, 14, 211-219.	1.0	21
244	Quality of leucoreduced red blood cell concentrates: 5Âyears of follow-up in France. Vox Sanguinis, 2008, 94, 41-47.	1.5	18
245	Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. Journal of Viral Hepatitis, 2008, 15, 255-260.	2.0	21
246	Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study “ ANRS HC02. Journal of Hepatology, 2008, 48, 765-773.	3.7	87
247	Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV“HCV co-infected patients on HCV therapy. Journal of Hepatology, 2008, 49, 892-898.	3.7	13
248	“valuation de l'incidence de la cirrhose biliaire primitive en 2007 en France. Revue Francophone Des Laboratoires, 2008, 2008, 25-28.	0.0	0
249	Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies. American Journal of Epidemiology, 2008, 167, 775-785.	3.4	927
250	Risk factors for grade 3 or 4 gamma-glutamyl transferase elevation in HIV/hepatitis C virus-coinfected patients. Aids, 2008, 22, 1234-1236.	2.2	6
251	How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited. Clinical Chemistry, 2008, 54, 1372-1378.	3.2	119
252	Progression of Fibrosis in HIV and Hepatitis C Virus-Coinfected Patients Treated with Interferon plus Ribavirin-Based Therapy: Analysis of Risk Factors. Clinical Infectious Diseases, 2008, 46, 768-774.	5.8	55



#	ARTICLE	IF	CITATIONS
253	Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. <i>Aids</i> , 2008, 22, 1385-1387.	2.2	6
254	Serum alpha-fetoprotein predicts virologic response to Hepatitis C treatment in HIV coinfected patients. <i>Aids</i> , 2008, 22, 1513-1515.	2.2	3
255	Rapid and early virological response to chronic hepatitis C treatment with IFN $\alpha$ 2b or PEG-IFN $\alpha$ 2b plus ribavirin in HIV/HCV co-infected patients. <i>Gut</i> , 2007, 56, 1111-1116.	12.1	46
256	High hepatitis C virus viral load in HIV/hepatitis C virus-co-infected patients: a different influence of protease inhibitor and non-protease inhibitor-based HAART?. <i>Aids</i> , 2007, 21, 1645-1648.	2.2	16
257	Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005) Tj ETQq1 1 0.784314 rgBT /Overlock	2.2	53
258	Early Virologic Failure in HIV-Coinfected Hepatitis C Patients Treated With the Peginterferon-Ribavirin Combination. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2007, 45, 123-125.	2.1	85
259	Viral pneumonia and respiratory sepsis: Association, causation, or it depends?*. <i>Critical Care Medicine</i> , 2007, 35, 639-640.	0.9	2
260	General practitionersâ€™ management of influenza with or without neuraminidase inhibitors. <i>European Journal of General Practice</i> , 2007, 13, 157-159.	2.0	1
261	Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. <i>Journal of Viral Hepatitis</i> , 2007, 14, 639-644.	2.0	24
262	The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. <i>Value in Health</i> , 2007, 10, 98-116.	0.3	60
263	Online detection and quantification of epidemics. <i>BMC Medical Informatics and Decision Making</i> , 2007, 7, 29.	3.0	50
264	Predicting Pneumonia and Influenza Mortality from Morbidity Data. <i>PLoS ONE</i> , 2007, 2, e464.	2.5	26
265	Risk Factors for Acute Liver Enzyme Abnormalities in HIV-Hepatitis B Virus-Coinfected Patients on Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2007, 12, 1115-1126.	1.0	8
266	Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. <i>Journal of Hepatology</i> , 2006, 44, 455-461.	3.7	79
267	Repeated influenza vaccination of healthy children and adults: borrow now, pay later?. <i>Epidemiology and Infection</i> , 2006, 134, 63-70.	2.1	27
268	Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. <i>Epidemiology and Infection</i> , 2006, 134, 514-520.	2.1	25
269	Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. <i>Aids</i> , 2006, 20, 419-427.	2.2	107
270	A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. <i>Journal of Viral Hepatitis</i> , 2006, 13, 775-782.	2.0	85

#	ARTICLE	IF	CITATIONS
271	A virologic survey of patients admitted to a critical care unit for acute cardiorespiratory failure. Intensive Care Medicine, 2006, 32, 156-159.	8.2	31
272	A 'small-world-like' model for comparing interventions aimed at preventing and controlling influenza pandemics. BMC Medicine, 2006, 4, 26.	5.5	88
273	Hepatic steatosis in HIV/HCV coinfecting patients: analysis of risk factors. Aids, 2006, 20, 525-531.	2.2	77
274	Heterosubtypic Immunity to Influenza: Right Hypothesis, Wrong Comparison. Journal of Infectious Diseases, 2006, 193, 1613-1613.	4.0	3
275	Comparison of Serum Hepatitis C Virus (HCV) RNA and Core Antigen Levels in Patients Coinfected with Human Immunodeficiency Virus and HCV and Treated with Interferon plus Ribavirin. Journal of Clinical Microbiology, 2006, 44, 417-422.	3.9	10
276	Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 47-52.	2.1	82
277	Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. Epidemiology and Infection, 2005, 133, 305-314.	2.1	9
278	Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment. Clinical Infectious Diseases, 2005, 41, 1806-1809.	5.8	41
279	The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology, 2005, 128, 297-303.	1.3	367
280	Influenza Epidemics in the United States, France, and Australia, 1972-1997. Emerging Infectious Diseases, 2004, 10, 32-39.	4.3	121
281	Detection of Lung Cancer on Radiographs: Receiver Operating Characteristic Analyses of Radiologists', Pulmonologists', and Anesthesiologists' Performance. Radiology, 2004, 233, 799-805.	7.3	40
282	Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2004, 292, 2839.	7.4	742
283	A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. Statistics in Medicine, 2004, 23, 3469-3487.	1.6	322
284	Chronic hepatitis C virus infection: Does it really impact health-related quality of life? A study in rural Egypt. Hepatology, 2004, 40, 1434-1441.	7.3	38
285	Exploring cross-protection between influenza strains by an epidemiological model. Virus Research, 2004, 103, 101-105.	2.2	24
286	Risk factors of influenza transmission in households. International Congress Series, 2004, 1263, 291-294.	0.2	97
287	A systematic analysis of all ICD10-coded death certificates in France, 2000, with a mention of influenza as cause of death. International Congress Series, 2004, 1263, 299-303.	0.2	2
288	Factors associated with intensity of symptoms in patients seeking medical advice for flu. International Congress Series, 2004, 1263, 308-311.	0.2	1

#	ARTICLE	IF	CITATIONS
289	Risk factors of influenza transmission in households. British Journal of General Practice, 2004, 54, 684-9.	1.4	241
290	Antibiotic Treatment for Influenza does not Affect Resolution of Illness, Secondary Visits or Lost Workdays. European Journal of Epidemiology, 2003, 19, 703-705.	5.7	14
291	Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine, 2003, 21, 3614-3622.	3.8	28
292	Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults. Pharmacoeconomics, 2003, 21, 215-224.	3.3	10
293	Prediction of the Spread of Influenza Epidemics by the Method of Analogues. American Journal of Epidemiology, 2003, 158, 996-1006.	3.4	107
294	Economic evaluations of neuraminidase inhibitors to control influenza. Expert Review of Pharmacoeconomics and Outcomes Research, 2003, 3, 147-158.	1.4	5
295	Influenza Burden of Illness. Archives of Internal Medicine, 2002, 162, 1842.	3.8	117
296	Primary biliary cirrhosis: Incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology, 2002, 122, 652-658.	1.3	168
297	Quality control of leucoreduced cellular blood components in France. Vox Sanguinis, 2002, 82, 67-71.	1.5	11
298	Quantifying the burden of influenza: a prospective household contact study in France. International Congress Series, 2001, 1219, 61-66.	0.2	1
299	How much are patients willing to pay for an earlier alleviation of influenza?. International Congress Series, 2001, 1219, 67-71.	0.2	1
300	Rapid flu test and neuraminidase inhibitors in healthy adults: a cost-benefit analysis. International Congress Series, 2001, 1219, 73-79.	0.2	0
301	Severe Accidental Hypothermia Treated in an ICU. Chest, 2001, 120, 1998-2003.	0.8	111
302	The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology, 2000, 32, 1196-1199.	7.3	265
303	Comparison of a New Method for the Direct and Simultaneous Assessment of LDL- and HDL-Cholesterol with Ultracentrifugation and Established Methods. Clinical Chemistry, 2000, 46, 493-505.	3.2	31
304	A Scale of Methodological Quality for Clinical Studies of Radiologic Examinations. Radiology, 2000, 217, 69-74.	7.3	36
305	Evaluation of Clinical Case Definitions of Influenza: Detailed Investigation of Patients During the 1995-1996 Epidemic in France. Clinical Infectious Diseases, 1999, 28, 283-290.	5.8	143
306	Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut, 1999, 45, 218-222.	12.1	84

#	ARTICLE	IF	CITATIONS
307	Effects of current and former cigarette smoking on the clinical course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 1403-1411.	3.7	179
308	Monitoring epidemiologic surveillance data using hidden Markov models. , 1999, 18, 3463-3478.		126
309	Risk of hepatitis C virus transmission to surgeons and nurses from infected patients: model-based estimates in France. <i>Journal of Hepatology</i> , 1999, 30, 765-769.	3.7	32
310	Air Pollution and Respiratory Drug Sales in the City of Le Havre, France, 1993-1996. <i>Environmental Research</i> , 1999, 81, 224-230.	7.5	19
311	Factors of Weight Loss in Patients With HIV and Chronic Diarrhea. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 34-39.	0.3	22
312	Effect of indinavir on HIV-related wasting. <i>Aids</i> , 1998, 12, 1777-1784.	2.2	51
313	A new out-patient care facility for HIV-infected destitute populations in Paris, France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 1997, 9, 451-459.	1.2	13
314	Influenza and influenza-like illness in general practice: drawing lessons for surveillance from a pilot study in Paris, France. <i>British Journal of General Practice</i> , 1997, 47, 217-20.	1.4	13
315	Influenza mortality among the elderly in France, 1980-90: how many deaths may have been avoided through vaccination?. <i>Journal of Epidemiology and Community Health</i> , 1995, 49, 419-425.	3.7	57
316	Consequences of Misdiagnosis of Intrauterine Growth Retardation for Preterm Elective Cesarean Section. <i>Fetal Diagnosis and Therapy</i> , 1993, 8, 325-330.	1.4	10
317	Epidemiologic Mapping using the "Kriging" Method: Application to an Influenza-like Epidemic in France. <i>American Journal of Epidemiology</i> , 1992, 135, 1293-1300.	3.4	152
318	Effect of Maternal and Fetal Characteristics on Diagnosis of Intrauterine Growth Retardation. <i>Fetal Diagnosis and Therapy</i> , 1990, 5, 114-123.	1.4	1
319	Seroprevalence of SARS-CoV-2 Among Adults in Three Regions of France Following the Lockdown and Associated Risk Factors: A Multicohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15
320	SARS CoV-2 Seroprevalence Among HIV-Negative Participants Using Tenofovir/Emtricitabine Based PrEP in 2020 - A Sub-study of ANRS PREVENIR and INSERM SAPRIS-Sero Cohorts. <i>Open Forum Infectious Diseases</i> , 0, , .	0.9	5